This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

8 Jun 2012

OncoSec & VGXI Enter into Immunotherapy Drug Agreement

OncoSec Medical has chosen VGXI Inc as its manufacturing partner for DNA IL-12.

Biopharmaceutical company OncoSec Medical has entered into an exclusive manufacturing agreement with DNA plasmid specialist VGXI Inc for the production of a new immunotherapy drug.


Interleukin-12 plasmid DNA (DNA IL-12) is being developed to treat solid cancerous tumours using OncoSec's advanced-stage OncoSec Medical System (OMS) ElectroImmunotherapy programme, which uses electrical stimulation to increase the entry of drugs into tumour cells.


The treatment is designed to selectively destroy cancer cells while preserving surrounding healthy tissue.


Under the agreement - financial terms of which have not been disclosed - VGXI's patented DNA plasmid manufacturing process will be used to support O

Related News